checkAd
    Startseite > Aktien > Xenon Pharmaceuticals > Nachrichten
    Xenon Pharmaceuticals Aktie
    42,49
     
    USD
    +4,53 %
    +1,84 USD
    Letzter Kurs 02:00:00 Nasdaq
    42,48
     
    USD
    1.800 STK
    Geldkurs 01.05.24
    42,51
     
    USD
    100 STK
    Briefkurs 01.05.24
    ISIN: CA98420N1050 · WKN: A12ETN · SYM: XENE · Kanada

    Neueste Nachrichten

    Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
    16.04.24 · globenewswire · Xenon Pharmaceuticals
    Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
    10.04.24 · globenewswire · Xenon Pharmaceuticals
    Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
    04.04.24 · globenewswire · Xenon Pharmaceuticals
    Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
    12.03.24 · globenewswire · Xenon Pharmaceuticals
    Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
    05.03.24 · globenewswire · Xenon Pharmaceuticals
    Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    29.02.24 · globenewswire · Xenon Pharmaceuticals
    Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
    22.02.24 · globenewswire · Xenon Pharmaceuticals
    Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
    08.01.24 · globenewswire · Xenon Pharmaceuticals
    Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    03.01.24 · globenewswire · Xenon Pharmaceuticals
    Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
    30.11.23 · globenewswire · Xenon Pharmaceuticals
    Xenon Pharmaceuticals Announces Proposed Public Offering
    29.11.23 · globenewswire · Xenon Pharmaceuticals
    Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
    27.11.23 · globenewswire · Xenon Pharmaceuticals